System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Félix Guerrero-Ramos is an expert in Urology at Hospital Universitario 12 De Octubre (Spain). As of October 2026, ScienceLeadR ranks Félix Guerrero-Ramos in the top 1% of experts worldwide for Urinary Bladder Diseases and Urologic Neoplasms. Félix Guerrero-Ramos has authored 257 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 9 of them ongoing. SLR score: 1,126 (community average: 125). How the SLR is computed.

LeadR Profile

Félix Guerrero-Ramos Hospital Universitario 12 De Octubre Spain
1 126 ScienceLeadR Reputation 1126

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1986 - 2026
Source: PubMed

Hospital Universitario 12 De Octubre

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 257

Citations

Citations: 6 387 1st author: 55 Last author: 27 Unique author: 6

Main journals

J Med Entomol 20
J Urol 18
J Clin Oncol 13
Actas Urol Esp (Engl Ed) 9
Curr Opin Urol 7

Best Journals

J Clin Oncol 12
Nat Med 3
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
CABOPRE: Evaluating Perioperative Cabozantinib's Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma.
PMID 42882910 — cells, neoplasms, nephrectomy, carcinoma, renal cell, biomarkers, therapeutics		Cancers (Basel)20260
Nephrology Consultation Patterns and Clinical Outcomes in Hospitalized Patients with Heart Failure.
PMID 42862653 — kidney diseases, creatinine, mortality, hospitalization, heart failure, heart, hospital mortality, kidney, nephrology, acute kidney injury		Kidney36020260
Durvalumab in Combination with Bacillus Calmette-Guérin Induction and Maintenance Therapy for Bacillus Calmette-Guérin-Naïve, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.
PMID 42713893 — urinary bladder, urinary bladder neoplasms, urology, safety, muscles, neoplasms, bacillus, maintenance, therapeutics, non-muscle invasive bladder neoplasms		J Urol20260
Perioperative and survival outcomes of synchronous vs. metachronous upper tract urothelial carcinoma among bladder cancer patients treated with radical cystectomy and nephroureterectomy: Results from an International Multicenter Collaborative Study-On behalf of the Young Academic Urology (YAU) Urothelial Working Group.
PMID 42701052 — urinary bladder, urinary bladder neoplasms, urology, neoplasms, cystectomy, nephroureterectomy		Urol Oncol20260
Feasibility and early outcomes of single-port robotic-assisted radical cystectomy with intracorporeal ileal conduit: an initial Spanish case series.
PMID 42582809 — urinary bladder neoplasms, cystectomy		Transl Androl Urol20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 7
Phase 3 6
Phase 1/Phase 2 4
N/A 1
Phase 1 1

By status:

Active not recruiting 8
Recruiting 4
Completed 2
Not yet recruiting 2
Terminated 2
Unknown 1

By type:

Interventional 18
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 3
multicentricup10 15

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non muscle invasive bladder cancer may come back or get worse
2024-512029-10-00 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, therapeutics, non-muscle invasive bladder neoplasms		Phase 3Not yet recruiting2025
A study to investigate dabogratinib (TYRA 300) in participants with Low Grade Upper Tract Urothelial Carcinoma
2025-523539-20-00 — safety, neoplasms, multiple chronic conditions, carcinoma		Phase 2Not yet recruiting2026
A study to learn about nadofaragene firadenovec given alone or together with gemcitabine and docetaxel or pembrolizumab in adults with non muscle invasive bladder cancer and no response to treatment with Bacillus Calmette Guerin
2024-512177-27-01 — urinary bladder, urinary bladder neoplasms, safety, muscles, docetaxel, neoplasms, multiple chronic conditions, bacillus, drug therapy, immunotherapy, therapeutics, carcinoma in situ, chemotherapy, non-muscle invasive bladder neoplasms, carcinoma		Phase 3Recruiting2025
A clinical study of V940 and BCG in people with bladder cancer (V940 011)
2024-517335-46-00 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, non-muscle invasive bladder neoplasms		Phase 2Recruiting2025
A clinical study of MK 3120 in people with bladder cancer (MK 3120 003)
2025-520467-40-00 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, carcinoma in situ, non-muscle invasive bladder neoplasms, carcinoma		Phase 1/Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS